To evaluate the cost-effectiveness of hepatic resection ("metastasectomy") in patients with metachronous liver metastases from colorectal carcinoma (CRC), and to investigate the impact of operative and follow-up strategies on outcomes, cost, and cost-effectiveness.
Summary Background Data
There is substantial evidence that resection of CRC liver metastases can result in long-term survival in some patients. However, several unresolved issues are difficult to address using currently available clinical data. These include the appropriate threshold for resection, whether to perform repeat resection, and the relative cost-effectiveness of the procedure(s).
Methods
The authors developed a state-transition Monte Carlo decision model to evaluate the (societal) cost-effectiveness of hepatic metastasectomy in patients with metachronous CRC liver metastases. The model tracks the presence, number, size, location, growth, detection, and removal of up to 15 individual metastases in each patient. Survival, quality of life, and cost are predicted on the basis of disease extent. Imaging and surgery affect outcomes via detection and removal of individual metastases. Several patient management strategies were developed and compared with respect to cost, effectiveness, and incremental cost-effectiveness ($/quality-adjusted life year [QALY]). A reference strategy in which metas-tasectomy is not offered and imaging is not performed for the purpose of assessing resectability or operative planning ("nosurgery" strategy) was included for comparison. Extensive sensitivity analysis was performed to evaluate the impact of alternative model assumptions on results.
Results
A strategy permitting resection of up to six metastases and one repeat resection, with CT follow-up every 6 months, resulted in a gain of 2.63 QALYs relative to the no-test/no-treat strategy, at an incremental cost of $18,100/QALY. When additional surgical strategies were considered, the incremental cost-effectiveness ratio (ICER; relative to the next least effective strategy) of the six metastases, one repeat, 6-month strategy was $31,700/QALY. Across a range of model assumptions, more aggressive treatment strategies (i.e., resection of more metastases, resection of recurrent metastases) were superior to less aggressive strategies and had ICERs below $35,000/QALY. Findings were insensitive to changes in most model parameters but somewhat sensitive to changes in surgery and treatment costs.
There is substantial evidence that resection of liver metastases from colorectal carcinoma (CRC) can result in long-term survival in some patients. However, a number of issues remain unresolved and have proven difficult to address on the basis of data from clinical series. These include the appropriate threshold for resection (generally based on the number of metastases detected), whether to perform repeat metastasectomy, and the relative cost-effectiveness of the procedure. To address these issues, and in recognition of the limits inherent in currently available clinical trial data, we undertook an investigation of the cost-effectiveness of hepatic metastasectomy in patients with CRC liver metastases. The analysis focuses on patients who have previously undergone resection of a primary CRC and are known to have developed metachronous liver metastases.
METHODS
The principal focus of the analysis was to determine the relative cost-effectiveness of hepatic metastasectomy in patients with metachronous CRC metastases. A "base case" analysis (i.e., using our best estimates for all model parameters and event probabilities) was performed from a societal perspective following the consensus recommendations of the U.S. Department of Health and Human Services Panel on Cost-Effectiveness in Health and Medicine. 24 -27 Sensitivity analyses were performed across a range of assumptions concerning the number of metastases per patient, the rate of tumor growth, operative mortality, disease-related mortality and quality of life, the costs of surgery and patient care, the discount rate used for both costs and life years, and patient age.
Cost-Effectiveness Model
We developed a state-transition Monte Carlo decision model 28 -30 shown in Figure 1 . The model contains only three states: alive_res, alive_nores, and dead. All patients begin in the alive_res state. Patients in the alive_res state are potential candidates for resection. Patients move to the alive_nores state when they have either been found to be "unresectable" (i.e., to have more metastases than the threshold for metastasectomy in the strategy under consideration) or when they have had the maximum allowable number of resections for the strategy under consideration. The dead state is self-explanatory.
At the end of each cycle, patients return to one of the three model states according to event and transition probabilities defined in the model. This process continues until all patients in the initial cohort reach the dead state, at which point the simulation is terminated. The model includes only one generic imaging and treatment strategy, which is defined using specific model parameters (e.g., operative threshold, image/treat interval, test sensitivity). For each set of model assumptions and each specific imaging and treatment strategy under consideration, we simulated hypothetical cohorts of 10,000 patients.
The model tracks up to 15 individual hepatic metastases in each patient, specifying and updating tumor location, size, rate of growth, detection, and removal (if it occurs). It includes more than 300 parameters and 75 associated independent probability distributions that specify patient, tumor, test, and treatment characteristics and define event probabilities. Many of these model parameters are so-called tracker variables, which are used to keep track of patient and/or tumor characteristics, and thereby simplify the model structure. The model was analyzed by simulating cohorts of hypothetical patients, one at a time, from initial presentation until death (1-month cycle length), while tracking disease progression, diagnostic tests, procedures, complications, survival, and costs.
For each hypothetical patient, the number of metastases present is drawn at random from a population distribution. Metastases are then distributed throughout the liver. We assume that each metastasis has an independent, equal probability of being located in each of the eight liver segments. [31] [32] [33] The size of each metastasis is similarly drawn at random from a population distribution. Over time, metastases grow, may be detected by imaging tests, and may be removed during resection. Growth in tumor volume is assumed to be exponential, at rates determined from the literature. 34 We used a single point estimate (i.e., rather than a distribution about that estimate) to represent the average tumor doubling time, since it was found that the use of a distribution had no effect on model results. We assume that no new liver metastases develop over time, since all patients are assumed to be status post removal of their primary tumors. However, metastases can be missed at initial diagnosis but can later be detected on repeat imaging tests. Such metastases would account for the "new metastases" reported in clinical series, which were probably present but undetected earlier. [35] [36] [37] The frequency with which follow-up imaging tests are performed is explicitly modeled. Each time a patient undergoes a diagnostic imaging test, metastases may be (independently) detected or missed. Tumor detection is based on test sensitivity, although it is assumed that below a certain (definable) size threshold, all metastases are missed. We assume that helical, contrast-enhanced CT scanning is used in all patients.
On the basis of the CT results, a decision is made regarding the candidacy of each patient for metastasectomy. We allow the possibility of different criteria for determining surgical candidacy, depending on the number of metastases identified (Յ1, 3, or 6) and the number of hepatic segments involved (Յ6). At surgery, additional metastases may be found, either by palpation of the liver or intraoperative ultrasound. The detection of these additional metastases could influence the decision to proceed with metastasectomy, and/or modify the plan for resection.
As a result of metastasectomy, patients are either free of metastatic disease or have residual metastases, depending on the number and location of metastases detected, the location of metastases not detected, and the operation performed. We assume that each segment in which at least one metastasis is detected is resected, and that segments in which no metastases are detected are not resected. Thus, all tumors located in resected segments are removed, while tumors located in segments that are not resected are not removed. Patients may also suffer operative morbidity or mortality. Each of these events is explicitly modeled.
Parameter Estimates
Model parameters were estimated from the literature where valid data were available, and otherwise on the basis of expert opinion. Base case estimates and ranges used in sensitivity analyses are summarized in Table 1 .
We assumed that the number of metastases per patient could be approximated by a Poisson distribution, and used for our base case analysis a population mean of six metastases per patient, based on literature concerning resectability and recurrence rates, 38 -40 as well as data on 1,718 patients from Erlangen University Hospital records from 1960 to 1992. 17 Tumor volume is an important determinant of survival. 16, [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] We estimated mean tumor diameter at 2.5 cm and assumed that tumor diameter, at the time that metastatic disease becomes clinically suspected, was approximated by a gamma distribution. Our estimate of initial tumor size was based on reports from surgical series, 15, 17, 20, 51, 52 autopsy series, 32 and the imaging literature. 53, 54 Tumor volume doubling time was estimated based on a study by Finlay et al., 34 who measured tumor volume on CT scans for up to 3 years in patients with CRC liver metastases. Normal liver volumes for adult men and women were 55 who measured liver volume in adult patients with normal livers whose disease conditions did not appear to affect either body weight or liver volume. We assumed that the liver regenerates to normal volume following subtotal resection. 56 We did not specifically model the rate of liver regeneration, but rather assumed that the liver would return to normal volume by the time a patient might be considered for repeat resection (i.e., the follow-up interval). We also did not specifically model any increased morbidity or mortality due to transiently decreased liver volume, except to the extent that this may have been incorporated into reported (generally 30-day) morbidity and mortality figures.
We estimated the probability of morbidity and mortality associated with hepatic metastasectomy as 0.2 and 0.05, respectively. 3, 4, 10, 11, 17, 22, 52, [57] [58] [59] [60] The limited data that are available concerning repeat hepatic resections 35, 38, 39, 56 suggest that these can be performed with morbidity and mortality comparable to those seen with initial resections. We therefore used the same estimates for the probability of morbidity and mortality for all instances of hepatic metastasectomy. We estimated the probability of morbidity and mortality associated with laparotomy (patients found at surgery to be unresectable) as 0.04 and 0.01, respectively.
We used 0.80 as our base case estimate for the sensitivity of CT. No studies have yet reported results using currentgeneration multidetector row helical CT in patients with known or suspected hepatic metastases, and few 53,61,62 have reported results using conventional helical CT. The two most recent studies 53,61 report sensitivities of 0.76 and 0.71 for conventional helical CT. In view of these reports, and taking into account our modeling approach (i.e., the use of a minimum detection threshold in combination with detection sensitivity), we feel that the use of 0.80 as a sensitivity for CT is realistic, given currently available CT technology. Our estimate of the size threshold for tumor detection was based on the literature [62] [63] [64] [65] [66] [67] [68] [69] and personal experience.
The combination of intraoperative ultrasound and palpation of the liver is widely accepted to be the most sensitive method to detect focal hepatic metastases. 70 -76 We used 0.95 as our base case estimate of intraoperative ultrasound sensitivity. There is a lower limit to the size of metastases that can be resolved using even high-frequency intraoperative scanning equipment and meticulous technique. This was estimated at 3 mm on the basis of published reports 75, 77, 78 that reported the detection of metastases as small as 2.0 ϫ 3.0 mm, and guided by our clinical experience, where lesions down to 3 to 5 mm are routinely identified.
Outcomes
Several studies have described the "natural history" of patients with untreated metastases. 16, [43] [44] [45] [46] [47] [48] [49] [50] Though these reports have spanned three decades and represent the experi- Cost-Effectiveness of Hepatic Metastasectomy ence at several institutions in different countries, they are remarkably consistent. The single most important determinant of survival appears to be the extent of liver replacement by tumor (LVRT). Different investigators have reported liver involvement using different criteria. These include less than 25% versus 25% or more LVRT; 44, 48, 50 unilateral versus bilateral metastases; 43, 45, 47, 49, 50 and less than four versus four or more metastases. 16, 46, 47 Each of these criteria is likely to have divided patients along roughly the same lines (e.g., patients with unilateral metastases are unlikely to have Ն25% LVRT). Furthermore, estimates of median survival based on the different categorizing criteria are similar. We assigned to patients with less than 25% LVRT a median survival of 11.5 months, and to patients with at least 25% LVRT a median survival of 6.3 months, based on a weighted average of the studies reporting survival as a function of %LVRT. 44, 48, 50 Because we explicitly modeled the number, size, and growth of all metastases, it was possible to calculate %LVRT in each patient and to revise it with each cycle of the model. State-to-state transition probabilities for patients with liver metastases were calculated from the corresponding estimated median survivals, assuming constant hazard rates (i.e., exponential survival curves). 79, 80 For our base case analysis, we assigned patients without liver metastases mortality hazard rates twice as high as the age-and sex-adjusted rates for the U.S. population (as reported in the 1988 U.S. Life Tables). We also used data from the National Cancer Institute's Survival, Epidemiology, and End-Results (SEER) to guide our estimates of hazard rate in patients with no metastases. To estimate hazard rates for the analyses using the SEER database, the age-and sex-specific 1-year survival probabilities were used to calculate the hazard rates by age and sex for patients with "localized" disease. The hazard rates for patients with "localized" disease derived from the SEER data are approximately the same as those assigned to patients with no metastases in our base case analysis. Higher mortality hazard rates were considered in sensitivity analyses; see below for details. Unlike actual patients, who might appear to have no metastases but actually have undetected metastases (and therefore excess mortality due to their metastases), patients who are categorized in our model as having no metastases truly have no (liver) metastases, since we model the true extent of liver metastases in each patient.
Quality-adjusted life years (QALYs) were used as the primary endpoint with which to assess the effectiveness of each of the testing strategies. We assigned years of life without hepatic metastases QALY weights equal to age-and sex-adjusted population values. 81 The limited data that are available 82, 83 regarding quality of life (QOL) in patients with metastatic colorectal carcinoma suggest that the majority (approximately 95%) of survival is spent with normal (age-adjusted) QOL. QOL then declines rapidly at the end of life (median: last 12 days). We therefore modeled QALYs by subtracting a toll in the final cycle (month) before death, estimating that QOL in the month before death was 60% of that for age-and sex-matched controls. QALY tolls were also assessed to account for decreased QOL following hepatic metastasectomy or laparotomy. We estimated that QOL in the month following surgery was 70% of that for age-and sex-matched controls.
Costs
Costs were estimated from a societal perspective. Costs from prior years were converted to 1998 dollars using the medical care component of the Consumer Price Index (U.S. Bureau of Labor Statistics). For the base case analysis, all costs and QALYs were discounted at a real annual rate of 3% to adjust for the relative value of present dollars or a present year of life. Base case estimates for all costs are summarized in Table 2 .
Costs of the diagnostic tests were determined on the basis of the Medicare payment schedule. We assumed that all preoperative diagnostic CT scans would be performed on an outpatient basis and therefore used the Medicare reimbursement rate based on CPT code 74160 ($373). We assumed that intraoperative ultrasound would be used in all patients undergoing metastasectomy. Because this procedure is performed during an inpatient hospitalization (and therefore its technical cost included in the global DRG-based cost estimate), we estimated its cost ($56) based on CPT code 76986 -26, corresponding to only the professional component.
Direct medical costs of liver resection were derived from the Medicare reimbursement rates corresponding to the appropriate DRG and CPT codes, based on the Resource-Based Relative Value Scale. DRG codes were used to derive cost estimates for hospital (part A) costs, while CPT codes were used to derive cost estimates for physician (part B) costs. Two specific DRG codes were relevant: DRG 191 (Pancreas, Liver, and Shunt Procedures with Comorbidity/ Complications) and DRG 192 (Pancreas, Liver and Shunt Procedures without Comorbidity/Complications). We used a weighted average of the reimbursement rates associated with these DRG codes, based on an analysis of the coding of all patients who underwent major hepatic resection (DRG 191/192 and CPT 47120, 47122, 47125, or 47130) at our institution in fiscal year 1998. Approximately 12% of these patients were coded using DRG 192, while the remaining patients were coded using DRG 191. In 1998, the reimbursement rates for DRG codes 191 and 192 were $25,173 and $9,399, respectively. We therefore estimated the hospital costs for hepatic metastasectomy at $23,317.
Professional costs related to liver resection were derived from the 1998 Medicare reimbursement rates (part B) for the appropriate CPT codes. For the base case estimate we used a simple average ($1,808) of the reimbursement rates associated with CPT codes 47120 ($1,295), 47122 ($2,017), 47125 ($1,868), and 47130 ($2,238), representing partial resection, trisegmentectomy, left lobectomy, and right lobectomy, respectively.
The technical and professional costs of a laparotomy (patients in whom additional metastases are discovered in the operating room may undergo only laparotomy rather than resection as planned) were similarly derived. Because there is no DRG code specifically applicable to laparotomy in this setting, and because patients found to be unresectable at the time of surgery (i.e., on the basis of intraoperative ultrasound and/or palpation of the exposed liver) would generally be coded according to DRG 191 or 192, we elected to use the hospital reimbursement rate associated with DRG 192 (Pancreas, Liver and Shunt Procedures without Comorbidity/Complication) as a proxy for laparotomy cost. We used the lower of the two possible rates in patients who do not actually undergo liver resection, because we felt that resource use associated with laparotomy would be more closely approximated by the lower rate.
For the cost of complications related to hepatic resection, we used the estimated median hospitalization (3 days) required for each complication reported from a prospective multi-institutional study of hepatic resection in patients with metastatic colorectal cancer. 52 We used the estimated perdiem intensive care unit costs among patients with DRG codes 191 and 192 who underwent hepatic resection at our institution in fiscal year 1998 as a proxy for the daily cost in patients experiencing complications of resection. These cost estimates were derived using software from Eclypsis, Inc. (previously Transition Systems, Inc.), which interfaces with the hospital accounting system and can access patient records according to DRG and/or CPT codes, admitting and/or discharge diagnosis, or principal procedure performed, among other criteria.
The cost of complications related to laparotomy was similarly calculated. We estimated that, on average, complications in patients undergoing laparotomy would also require 3 additional days of hospitalization. However, it was felt that in most cases, resource use during these 3 days would be considerably less than for patients sustaining resection-related complications. We therefore used as a proxy the estimated per-diem routine (i.e., non-intensive care unit) care costs among patients having DRG codes 191/192 who underwent hepatic resection at our institution in fiscal year 1998. These estimates were derived using the Eclypsis software described above.
There is a cost associated with dying from surgery, as most deaths do not occur during or immediately after the procedure. This was estimated as the cost of 5 intensive care unit days using the per-diem intensive care unit cost, as described above. We also added an estimate of physician costs related to caring for these patients for 5 days.
The cost of care for patients with local and metastatic colorectal cancer was estimated from the literature. Taplin et al. in 1995 reported a detailed analysis of the costs of caring for patients with colon, prostate, and breast cancer, 84 based on tumor stage at the time of diagnosis, as well as age and comorbidity. We estimated costs for patients with no metastases, limited (Յ25% LVRT) metastases, and extensive (Ͼ25% LVRT) metastases based on the stage-specific costs reported in this study. For patients with no metastases we used a weighted average of the costs reported for continuing care of patients with carcinoma in situ, local disease, and regional disease at diagnosis ($6,323/yr). For patients with limited metastases we used the cost reported for continuing care of patients with distant disease at diagnosis ($23,411/yr). For patients with extensive metastases we We estimated the time required for CT scanning as approximately 0.5 days, including the time associated with travel, waiting, and diagnostic imaging. The length of hospitalization required for liver resection, laparotomy, and complications of both procedures was estimated to be 12, 5, and 3 days, respectively. Length-of-stay data for resection were derived from patient records and from HCFA (Bureau of Data Management and Strategy) public use files. Estimates for length of hospitalization for patients undergoing only laparotomy were derived from patient records at our institution. We did not include the costs of transportation, care by family and friends, or household modification related to either diagnostic testing or treatment, since the magnitude of any differences in these costs between strategies was not felt to be sufficient to justify the added complexity.
Model Verification
Both to demonstrate the ability of the model to reflect those variables of interest that we can identify and measure, and to calibrate the parameters of the model to account for influences we cannot measure directly, we compared model-generated cohorts with actual patient data for existing management strategies. This process helped to ensure accurate and realistic cost and outcome projections, not only for currently available imaging and treatment techniques, but also for management strategies, therapies, and newly developed technologies for which adequate actual patient data do not yet exist. To perform this verification procedure, we disabled discounting, cost calculations, and QOL adjustment in the model and simulated cohorts of patients undergoing imaging and treatment strategies similar to those reported in the surgical literature. We then specifically compared the predicted rates of resectability, 5-year survival, and tumor recurrence following resection for existing management strategies with those reported in the literature.
Analyses Performed
The model was analyzed as a first-order Monte Carlo simulation using cohorts of 10,000 patients. Sample size was determined adaptively to achieve convergence of estimates and separation of strategies in terms of cost, effectiveness, and cost-effectiveness. Multiple patient management strategies were developed and compared. These differed with respect to the maximum number of metastases that might be removed (1, 3, or 6) , whether repeat resection was permitted, and the interval at which follow-up imaging and repeat resection might be performed (4, 6, or 12 months). A "no-surgery" strategy (in which nonsurgical therapies such as chemotherapy and related diagnostic tests are permitted) was included as a reference against which to compare other strategies.
Base case analysis was performed using cohorts of 65year-old men, a 3% discount rate for both cost and effectiveness, and estimates for costs, treatment effectiveness, and other event probabilities as described above. We simulated all possible combinations of follow-up interval (4, 6, or 12 months), maximum number of resections allowed (1 or 2), and the threshold for operating (1, Յ3, or Յ 6 metastases identified). Strategies were compared with respect to total costs and QALYs, from which incremental cost-effectiveness ratios were calculated. Strategies that cost more but yield lower total benefits ("dominated") or those that have a higher incremental cost-effectiveness ratio than the next most costly and effective strategy ("weakly dominated") were eliminated.
Extensive sensitivity analysis was performed to investigate the effects of changes in model parameters on estimated costs and effectiveness outcomes. The following parameters were varied: patient age, mortality hazard rates (patients with and without metastases), number of metastases, tumor volume doubling time, discount rate, costs of resection and laparotomy, costs of patient care, QOL weights assigned for patients with metastases, and thresholds for tumor detection at imaging and surgery. Additional analyses were performed in which several of the parameters were simultaneously varied, in an attempt to define circumstances unfavorable to surgery. For example, as a worstcase scenario, we compared the resection strategies with the hazard rate increased fivefold in patients with no metastases, tumor doubling time doubled (i.e., slowed), the threshold for CT detection increased to 1 cm, and the threshold for intraoperative detection increased to 0.5 cm. Each of these changes in model parameters would tend to bias the results against surgery, either by making the treatment less effective in an absolute sense (e.g., increasing the hazard rate in patients whose metastases were successfully removed) or by improving survival in patients with untreated metastases (and thereby decreasing the incremental benefit of hepatic metastasectomy). For each change in model parameters, we repeated a complete set of simulations (cohorts of 10,000 patients) comprising all possible combinations of follow-up interval (4, 6, or 12 months), maximum number of resections allowed (1 or 2), and the threshold for operating (1, Յ3, or Յ 6 metastases identified). Table 3 reports the results of our model verification simulations. Our model predicts that 3% to 77% of patients (65-year-old men) would appear resectable, depending on the operative threshold. Predicted liver recurrence rates following resection range from 41% to 51%. These estimates appear fairly stable across a range of operative thresholds and are consistent with the published literature (42-49%). 7, 8, 11, 36, 37, 49, [85] [86] [87] [88] Predicted 5-year survival following metastasectomy ranges from 31% to 35%, which is consistent with the surgical literature (25-39%). 3,5-8,10 -12,14,17,18,20 -22,57 We feel that these results support our choice of model parameters and the modeling approach in general.
RESULTS

Model Verification
To investigate the effect of large changes in model parameters (i.e., changes that might result in significant changes in the relative cost-effectiveness of different management strategies via their impact on patient outcomes), we simulated a worst-case strategy (see above). This combination of model parameters resulted in predicted rates of tumor recurrence (27-41%) and 5-year survival (7-11%) following hepatic metastasectomy inconsistent with the published literature. These results suggest that the worstcase scenario is unrealistic.
Base Case Analysis
The results of the base case analysis are summarized in Table 4 . After eliminating dominated and weakly dominated strategies (see above), four strategies remain. These are presented in order of increasing incremental cost-effectiveness ratios (ICERs). For example, a typical strategy involving a 6-month follow-up interval, the resection of no more than six metastases, and up to one repeat metastasectomy had an ICER of $31,700/QALY, and the most aggressive strategy had an ICER of $62,700/QALY (compared to the next least effective nondominated strategy).
Sensitivity Analysis
The results of the sensitivity analysis are summarized in Table 5 . To permit comparison across scenarios, we list average cost, effectiveness, and ICERs for a representative Cost-Effectiveness of Hepatic Metastasectomy strategy involving a 6-month follow-up interval, an operative threshold of six or fewer metastases seen, and up to one repeat resection, relative to a "no-surgery" strategy (this presentation differs from the base case analysis, where all nondominated strategies are included in the comparison). Throughout a range of parameter estimates, the ICER of this strategy (compared directly to a "no-test/no-treat" strategy) was less than $25,000/QALY. When all patient management strategies were considered (results not shown), more aggressive strategies (i.e., resection of more metastases, resection of recurrent metastases) were superior to less aggressive strategies and had ICERs below $35,000/QALY (again, across a range of parameter estimates). Estimates for the worst-case model are also included in Table 5 . With this combination of model parameters, the benefits of metastasectomy decrease, with a corresponding increase in incremental cost-effectiveness. However, we feel that the fairly extreme parameter estimates used in the worst-case scenario are inconsistent with the available data (see above).
DISCUSSION
The results of our study suggest that hepatic metastasectomy is a relatively cost-effective management strategy for patients with limited hepatic metastases from CRC. Across a range of assumptions concerning model parameters, a strategy including resection of up to six metastases, a 4-to 6-month follow-up interval, and up to one repeat metastasectomy had an incremental cost-effectiveness ratio of less than $25,000/QALY, relative to a no-test/no-treat reference strategy. Furthermore, throughout the analysis, more aggressive strategies were superior to more conservative strategies. These results suggest that surgeons should be encouraged to select patients for metastasectomy on the basis of technical resectability, rather than numeric thresholds, and to pursue repeat resection when new lesions are identified following initial metastasectomy. Our results suggest that increasing the threshold for operative candidacy could result in moderate population-wide QALY gains.
The results were relatively insensitive to changes in model parameters but relatively more sensitive to changes in assumptions concerning the number of metastases present in each patient (i.e., the population distribution used to model the number of metastases in each patient), the size thresholds used for tumor detection (both preoperative and intraoperative), the costs of surgery and patient care, and the mortality hazard rates assigned to patients without metastases. Changing patient age, tumor doubling time, hazard rate in patients with liver metastases, discount rate, cost of surgery, cost of patient care, and the method used for QOL adjustment in patients with metastases had little effect on our results. The sensitivity to the number of metastases present is neither surprising nor particularly problematic. Because metastasectomy is generally offered only to patients with limited hepatic metastases (and in fact is more difficult to perform once more than four or five metastases are identified), we expect the therapy to appear less attractive as the number of metastases actually present increases. However, even under the assumption that the average number of metastases per patient is 10 (base case ϭ 6), the strategy that included 6-month follow-up, no more than six metastases seen, and one repeat resection had an ICER of $24,700/ QALY (relative to a no-test/no-treat strategy). In addition, while increasing the number of metastases present per patient did increase the ICER of surgery, its predominant effect was to dramatically decrease the fraction of patients who would be selected for metastasectomy, and thus decrease the average effectiveness, cost, and total gain in life expectancy (which might be expected across a population) of even the most aggressive management strategy.
As with the sensitivity to the number of metastases present, the sensitivity to detection thresholds is not surprising. Because of the way in which we modeled both preoperative and intraoperative tumor detection (probabilistic above a detection threshold, zero below it), changes in the detection thresholds would be expected to result in noticeable changes in the number of missed metastases, and consequently in the number of patients who would either be found at surgery to have additional metastases (and thus undergo only laparotomy) or develop "tumor recurrence" following metastasectomy. In either case (i.e., laparotomy or resection in patients with undetected metastases), the benefit of surgery would be decreased, as patients would face associated morbidity and mortality risks and accrue the costs of surgery, but nevertheless be left with metastases. We feel that the detection thresholds used in our base case analysis are easily obtainable using today's CT and intraoperative ultrasound equipment and techniques. 75 The sensitivity to the costs of surgery and patient care is also not particularly surprising: increasing or decreasing these costs would be expected to affect cost-effectiveness ratios. However, even when the cost of surgery or patient care is increased by 50%, the reference strategy had an ICER of less than $23,000/QALY. We did not specifically model chemotherapy costs, but rather used aggregate estimates for the costs of caring for patients based on their disease extent. Therefore, it was not possible to investigate the effects of chemotherapy costs (alone) on cost-effectiveness. However, we feel that our approach of increasing and decreasing overall patient care costs by 50% provides sufficient insight into the likely effects of increased or decreased chemotherapy costs.
The sensitivity to mortality hazard rate in patients with no metastases is somewhat more problematic. This does not apply to patients with undetected metastases (who might in routine clinical practice be considered to have no metastases based on imperfect imaging tests). As described above, we modeled the true number of liver metastases in each patient, rather than simply the results of imaging tests. The model assigns one of two hazard rates to all patients with liver metastases based on the percent of normal liver replaced by tumor, regardless of whether the metastases have actually been detected. However, we modeled only liver metastases. Because a small proportion of patients in whom all liver metastases have been removed will have extrahepatic metastatic disease (and thus would likely experience excess mortality due to their cancer), our base case analysis may underestimate the hazard rate in the entire group of patients who have no (liver) metastases. It is also possible that even patients who truly have no metastases (intrahepatic or extrahepatic) may still have excess mortality related to their prior history of CRC. Unfortunately, there are no data with which to derive hazard rates for patients with no liver metastases (who have a history of CRC and the possibility of extrahepatic metastases) following metastasectomy. As described above, we used data from the SEER database to guide our choice of mortality hazard rate in patients with no metastases. Our sensitivity analysis included comparisons in which the hazard rate was increased by 50% in patients with no metastases, which we feel covers a reasonable range for this parameter.
The principal limitations of our study relate to the uncertainty that surrounds some of our parameter estimates, as well as the necessary simplification of reality that was required to develop a tractable model. We have attempted to provide reasonable estimates for each of the specific model parameters and probability distributions, and to justify these estimates with references to the published literature and expert opinion and by validating the results of our simulations against published results from clinical trials. The greatest parameter uncertainty undoubtedly relates to life expectancy (and therefore our transition probabilities) in patients with no metastases (see above) and to a lesser extent, in patients with limited metastases. Few would dispute that patients with extensive liver metastases have an extremely poor prognosis. Our estimated life expectancy in these patients (i.e., those with Ն25% LVRT) of 6.3 months is supported by several published series. 16, 44, 48 However, patients who undergo hepatic metastasectomy are a highly selected subgroup of all patients with metastatic CRC, and it is difficult to estimate how long these patients might live without surgery. Our approach, by modeling the actual size and growth of individual metastases and basing life expectancy on %LVRT, seems reasonable; the only question is whether the hazard rate assigned to patients with limited metastases is too high. We addressed this issue via sensitivity analysis, in which the hazard rate in patients with metastases was increased or decreased by 50%, and found little change in results compared with the base case analysis. 
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The model developed for these analyses is a necessary simplification of reality, as is virtually every cost-effectiveness model. For example, we did not specifically model extrahepatic metastases, and though our results appear consistent with reported clinical series (with respect to tumor recurrence and 5-year survival, as described above), one must be careful not to generalize to populations that are dissimilar (e.g., where there is a much higher incidence of extrahepatic metastases).
Finally, there is certainly heterogeneity across patients with respect to virtually all model parameters, particularly those relating to outcome and cost. Through second-order Monte Carlo simulation ("probabilistic sensitivity analysis") it may be possible to assess the global impact of parametric uncertainty on model results. We did not attempt to assess the potential impact of population heterogeneity on our results because of the lack of data on which to base range estimates. Furthermore, superimposing a second-order simulation on our first-order Monte Carlo model is not possible in its current form. Additional data collection and analysis in this area may be of use in the future.
